Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MDCO-157 · 1 trial · 1 indication
To evaluate the dose-response of MDCO-157 (at 3 doses) compared to Plavix (300 mg), using Emax and AUEC with VASP, over 24 hours: * Maximum effect of P2Y12 receptor inhibition (Emax) using VASP (flow cytometry) * Area under the effect of P2Y12 receptor inhibition time curve (AUEC) using VASP (flow cytometry)
| Arm | Type | Description |
|---|---|---|
| 75mg MDCO-157 | ACTIVE_COMPARATOR | iv |
| 150mg MDCO-157 | ACTIVE_COMPARATOR | iv |
| 300mg MDCO-157 | ACTIVE_COMPARATOR | iv |
| 300mg PLAVIX | ACTIVE_COMPARATOR | oral |
| Name | Type | Description |
|---|---|---|
| MDCO-157 | DRUG | intravenous administration |
| PLAVIX | DRUG | oral administration |
Inclusion Criteria * Healthy males or females 18 to 45 years of age, inclusive. * Provide written informed consent for genetic testing and written informed consent for the study before initiation of any study related procedures * Affiliated to the French social security system * Screening and basel...
MDCO-157 is an investigational small molecule being studied for its pharmacokinetics and pharmacodynamics in healthy volunteers. It is currently in Phase 1 clinical development, with a completed trial that evaluated its properties in this population.
MDCO-157 is being developed by Novartis AG, a multinational pharmaceutical company. Novartis is listed on the stock exchange under the ticker symbol NVS.
MDCO-157 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and effects in humans.
MDCO-157 has one completed clinical trial, identified as NCT01860105. This Phase 1 study, titled 'Appraisal of MDCO-157 and Plavix® Pharmacokinetics and Pharmacodynamics in Healthy Volunteers With an Evaluation,' enrolled 37 participants in France.
No, MDCO-157 is not the same as Plavix. However, a clinical trial was conducted to compare the pharmacokinetics and pharmacodynamics of MDCO-157 with Plavix (clopidogrel) in healthy volunteers. The study was active-controlled, meaning Plavix served as the comparator.